# Endothelial MLKL Inhibition Reduces Hyperoxia‐Induced Bronchopulmonary Dysplasia in Neonatal Mice

**Authors:** Junjie Ning, Junchao Deng, Yating Sang, Lina Qiao

PMC · DOI: 10.1111/jcmm.71035 · 2026-01-29

## TL;DR

Inhibiting MLKL in endothelial cells reduces lung damage in neonatal mice exposed to high oxygen, offering a potential treatment for BPD in premature infants.

## Contribution

This study reveals that MLKL-mediated necroptosis in endothelial cells contributes to BPD and shows that inhibiting MLKL can mitigate lung injury.

## Key findings

- MLKL protein levels and gene expression are elevated in pulmonary vascular endothelial cells under hyperoxia.
- MLKL inhibition with NSA or conditional knockout in endothelial cells reduces hyperoxia-induced lung injury and preserves alveolar structure.
- Targeting MLKL in endothelial cells shows therapeutic potential for preventing or treating BPD in premature infants.

## Abstract

Bronchopulmonary dysplasia (BPD) remains a severe complication in premature infants requiring prolonged oxygen therapy, with vascular endothelial dysfunction recognised as a critical contributor to disease progression. Mixed lineage kinase domain‐like protein (MLKL)‐mediated necroptosis, an essential form of regulated cell death implicated in various pulmonary disorders, has not been fully investigated in the context of BPD. Here, we utilised a neonatal mouse model of hyperoxia exposure to elucidate the role and mechanisms of MLKL‐mediated necroptosis in BPD pathogenesis. Our analysis demonstrated morphological characteristics of necroptosis in pulmonary vascular endothelial cells (ECs) under hyperoxic conditions, accompanied by significant elevation of MLKL protein levels and marked upregulation of MLKL gene expression specifically in vascular ECs. Administration of the MLKL inhibitor necrosulfonamide (NSA), either immediately postnatally or at postnatal day 7, effectively mitigated lung injury, preserved alveolar structure and partially restored pulmonary vascular growth. Moreover, MLKL conditional knockout in ECs significantly attenuated both structural and functional pulmonary abnormalities induced by hyperoxia. Collectively, our findings indicate that MLKL‐mediated necroptosis in vascular ECs plays a pivotal role in hyperoxia‐induced BPD. Therapeutically targeting MLKL to maintain endothelial integrity presents a promising approach to prevent or alleviate BPD in premature infants.

## Linked entities

- **Genes:** MLKL (mixed lineage kinase domain like pseudokinase) [NCBI Gene 197259]
- **Proteins:** MLKL (mixed lineage kinase domain like pseudokinase)
- **Diseases:** Bronchopulmonary dysplasia (MONDO:0019091), BPD (MONDO:0001156)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ripk1 (receptor (TNFRSF)-interacting serine-threonine kinase 1) [NCBI Gene 19766] {aka D330015H01Rik, RIP, RIP-1, Rinp, Rip1}, RIPK3 (receptor interacting serine/threonine kinase 3) [NCBI Gene 11035] {aka RIP3}, Ripk3 (receptor-interacting serine-threonine kinase 3) [NCBI Gene 56532] {aka 2610528K09Rik, Rip3}, Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, Cdh5 (cadherin 5) [NCBI Gene 12562] {aka 7B4, Cd144, VE-Cad, VECD, VEcad, Vec}, Mlkl (mixed lineage kinase domain-like) [NCBI Gene 74568] {aka 9130019I15Rik}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Hmgb1 (high mobility group box 1) [NCBI Gene 15289] {aka HMG-1, Hmg1, SBP-1, p30}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, MLKL (mixed lineage kinase domain like pseudokinase) [NCBI Gene 197259] {aka hMLKL}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}
- **Diseases:** neurodevelopmental impairment (MESH:D009422), fibrosis (MESH:D005355), cavities (MESH:D003731), infection (MESH:D007239), tissue (MESH:D017695), fibrocystic lung disease (MESH:D054990), Hyperoxia (MESH:D018496), lung injury (MESH:D055370), endothelial dysfunction (MESH:D014652), lung ischaemia-reperfusion injury (MESH:D015427), necrosis (MESH:D009336), pulmonary inflammation (MESH:D011014), obstruction of pulmonary blood vessel (MESH:D009383), acute lung injury (MESH:D055371), inflammation (MESH:D007249), pulmonary abnormalities (MESH:D008171), alveolar dysplasia (MESH:C536590), BPD (MESH:D001997), Alzheimer's disease (MESH:D000544), disordered alveolar (MESH:D002282), oxygen toxicity (MESH:D000860), airway disease (MESH:D029424), pulmonary vascular remodelling (MESH:D066253)
- **Chemicals:** 95702S (-), xylene (MESH:D014992), citrate (MESH:D019343), TRIzol (MESH:C411644), SDS (MESH:D012967), glutaraldehyde (MESH:D005976), 4',6-diamidino-2-phenylindole (MESH:C007293), paraffin (MESH:D010232), CO2 (MESH:D002245), PBS (MESH:D007854), haematoxylin (MESH:D006416), NSA (MESH:C570695), osmium tetroxide (MESH:D009993), tamoxifen (MESH:D013629), acetone (MESH:D000096), EDTA (MESH:D004492), eosin (MESH:D004801), O2 (MESH:D010100), DPBS (MESH:C012939), uranyl acetate (MESH:C005460), H&amp;E (MESH:D006371), ATP (MESH:D000255), copper (MESH:D003300), reactive oxygen species (MESH:D017382)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** serine/threonine, C-26 C
- **Cell lines:** /6 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_5985), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12853218/full.md

---
Source: https://tomesphere.com/paper/PMC12853218